222 related articles for article (PubMed ID: 17602229)
21. [Clinical study of etanercept for treating ankylosing spondylitis].
Liang LQ; Zhan ZP; Ye YJ; Fu D; Xu HS; Yang XY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Aug; 28(8):1349-51. PubMed ID: 18753057
[TBL] [Abstract][Full Text] [Related]
22. TNF therapy for spondyloarthropathy: can we marshal the argument?
Dawes PT; Packham JC; Mucklow JC
Rheumatology (Oxford); 2004 Sep; 43(9):1069-71. PubMed ID: 15280568
[No Abstract] [Full Text] [Related]
23. Just released from the ASAS factory! First steps towards a disease activity score for ankylosing spondylitis.
Boers M
Ann Rheum Dis; 2009 Jan; 68(1):1-2. PubMed ID: 19088258
[No Abstract] [Full Text] [Related]
24. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
Rudwaleit M; Schwarzlose S; Hilgert ES; Listing J; Braun J; Sieper J
Ann Rheum Dis; 2008 Sep; 67(9):1276-81. PubMed ID: 18006539
[TBL] [Abstract][Full Text] [Related]
25. Fibromyalgia in between: where do the musculoskeletal physicians and psychiatrists stand?
Algül A; Basoglu C; Kiralp MZ; Ozçakar L
Acta Reumatol Port; 2008; 33(4):477-8. PubMed ID: 19107094
[No Abstract] [Full Text] [Related]
26. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Braun J; Baraliakos X; Listing J; Fritz C; Alten R; Burmester G; Krause A; Schewe S; Schneider M; Sörensen H; Zeidler H; Sieper J
Ann Rheum Dis; 2008 Mar; 67(3):340-5. PubMed ID: 17967831
[TBL] [Abstract][Full Text] [Related]
27. Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis.
Arends S; van der Veer E; Kallenberg CG; Brouwer E; Spoorenberg A
Curr Opin Rheumatol; 2012 May; 24(3):290-8. PubMed ID: 22418743
[TBL] [Abstract][Full Text] [Related]
28. Multiple sclerosis following etanercept treatment for ankylosing spondylitis.
Pfueller CF; Seipelt E; Zipp F; Paul F
Scand J Rheumatol; 2008; 37(5):397-9. PubMed ID: 18720264
[No Abstract] [Full Text] [Related]
29. 'It's magic stuff': the experiences of patients with ankylosing spondylitis taking anti-TNF-alpha medication.
Stockdale J; Goodacre L
Musculoskeletal Care; 2009 Sep; 7(3):162-77. PubMed ID: 19065621
[TBL] [Abstract][Full Text] [Related]
30. FDG-PET/CT scan of inflammatory spondylodiscitis lesions in ankylosing spondylitis, and short term evolution during anti-tumour necrosis factor treatment.
Wendling D; Blagosklonov O; Streit G; Lehuédé G; Toussirot E; Cardot JC
Ann Rheum Dis; 2005 Nov; 64(11):1663-5. PubMed ID: 16227425
[No Abstract] [Full Text] [Related]
31. Evidence in support of the validity of the TNF brake hypothesis.
Maksymowych WP
Ann Rheum Dis; 2013 Dec; 72(12):e31. PubMed ID: 23989987
[No Abstract] [Full Text] [Related]
32. Treatment of ankylosing spondylitis in patients refractory to TNF-inhibition: are there alternatives?
Kiltz U; Heldmann F; Baraliakos X; Braun J
Curr Opin Rheumatol; 2012 May; 24(3):252-60. PubMed ID: 22450391
[TBL] [Abstract][Full Text] [Related]
33. Restoration of overexpressed variable heavy chain 2 transcripts with tumor necrosis factor inhibitors in ankylosing spondylitis.
Sheen DH; Kim JY; Lee SY; Lim MK; Yoo SJ; Yoo IS; Kim J; Kang SW; Shim SC
J Rheumatol; 2014 Mar; 41(3):613-4. PubMed ID: 24585525
[No Abstract] [Full Text] [Related]
34. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
van der Heijde D; Lie E; Kvien TK; Sieper J; Van den Bosch F; Listing J; Braun J; Landewé R;
Ann Rheum Dis; 2009 Dec; 68(12):1811-8. PubMed ID: 19060001
[TBL] [Abstract][Full Text] [Related]
35. Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda-Gotor J; Pina T; González-Juanatey C; Llorca J; González-Gay MA
Ann Rheum Dis; 2014 May; 73(5):941-3. PubMed ID: 24323393
[No Abstract] [Full Text] [Related]
36. Ankylosing spondylitis: recent developments and anaesthetic implications.
Woodward LJ; Kam PC
Anaesthesia; 2009 May; 64(5):540-8. PubMed ID: 19413825
[TBL] [Abstract][Full Text] [Related]
37. Cutaneous leishmaniasis in a patient with ankylosing spondylitis using adalimumab.
Gomes KW; Benevides AN; Vieira FJ; Burlamaqui MP; Vieira Mde A; Fontenelle LM
Rev Bras Reumatol; 2012; 52(3):447-52. PubMed ID: 22641598
[TBL] [Abstract][Full Text] [Related]
38. Comment on: Monitoring Achilles enthesitis in ankylosing spondylitis during TNF-alpha antagonist therapy: an ultrasound study.
Knobloch K
Rheumatology (Oxford); 2010 Jul; 49(7):1418-9; author reply 1419-20. PubMed ID: 20360034
[No Abstract] [Full Text] [Related]
39. BSR guidelines for TNF blockers in ankylosing spondylitis--how useful are they?
Sheehy C; Murphy E; Barry M
Rheumatology (Oxford); 2006 Sep; 45(9):1176-7; author reply 1177-8. PubMed ID: 16820380
[No Abstract] [Full Text] [Related]
40. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents.
Montagna GL; Malesci D; Buono R; Valentini G
Ann Rheum Dis; 2005 Nov; 64(11):1667. PubMed ID: 16227427
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
